Q2 FY24 Quarterly Activities Report & Appendix 4C
Released
Released
Announcement PDF
ASX Announcement
30 January 2024
Q2 FY24 QUARTERLY ACTIVITIES REPORT & APPENDIX 4C
Strong personal testing growth, UK acquisition & successful Phase I trial
Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), a precision microbiome Company, is pleased to
provide a summary of its activities for the quarter ended 31 December 2023.
Key Highlights
•
Successful acquisition of United Kingdom microbiome company, Invivo Clinical in December. Invivo unaudited
Sales in 1H FY24* totalled $4.39m AUD.
•
Strong growth for MetaXplore healthcare test uptake. Over 1,000 Healthcare Professionals now registered.
•
Advanced Infectious Disease testing technology MetaPanel™, scheduled for full national launch with Sonic
Healthcare (ASX: SHL) in the current quarter.
•
Inflammatory Bowel Disease Program – Successful Phase I Clinical Trial completed, demonstrating MAP 315 is
safe and well tolerated.
•
Autoimmune Program – Ginkgo Bioworks (NYSE:DNA) Stage 1 Screening completed. 35 Strains selected for
Stage 2 Functional Screening, to be completed in the next quarter.
•
Second Agreement executed with IFF (NYSE: IFF) to develop novel microbiome-based treatments for multiple
forms of Allergy.
•
1H FY24 unaudited Revenue totalled $3.27m, up 52% on pcp.
•
Q2 FY24 unaudited Revenue totalled $2.19m^, up 79% on pcp with Personal Testing & Supplements up 119%^
to $1.51m and Research Testing up 28% to $0.68m.
•
Q2 FY24 Cash Receipts totalling $1.85m^, up 4.1% on the prior quarter and up 15.2% on pcp.
•
$27.85m in Cash or Equivalents at 31 December 2023, not including an estimated $6m FY23 R&D Tax Incentive.
Commenting on the quarter, Microba’s CEO, Dr Luke Reid, said:
“Microba’s testing revenue continue to grow. We have been laying down the foundations to bring microbiome testing into
healthcare and can see 2024 as a breakthrough year for the Company’s testing business. The acquisition of Invivo Clinical
supports our growth strategy with an established customer base in the United Kingdom and growth synergies. The upcoming
launch of our world-first advanced Infectious Disease test MetaPanel together with Sonic Healthcare is expected to be a pivotal
milestone.”
“Microba’s Therapeutic Development Programs continue to advance strongly. The Company successfully completed the Phase
I clinical trial of lead candidate MAP 315 under the Company’s Inflammatory Bowel Disease program, our Autoimmune
program with Ginkgo Bioworks (NYSE: DNA) moved into the Second and Final Stage of the discovery program, and we’ve
signed a Second Agreement to develop novel allergy treatments with IFF (NYSE: IFF). These results continue to validate
Microba’s therapeutic platform and the Company is set to continue advancement of these programs in 2024”
____________________________
* United Kingdom Financial Year H1 1 April to 31 September 2023
^ Invivo Clinical testing and supplement unaudited revenue and cash receipts included for the period of Microba’s ownership, from 5 to 31 December 2023
Microba Life Sciences Ltd ABN 82 617 096 652
Level 10, 324 Queen Street, Brisbane QLD 4000 Australia
T: 1300 974 621 E: investor@microba.com W: microba.com
ASX Announcement
30 January 2024
Successful acquisition of Invivo Clinical
Microba acquired 100% of the issued share capital in UK registered company, Invivo Clinical Limited (Invivo) on December 5,
2023. Unaudited sales in H1 FY24 totalled $4.39m AUD. The Invivo integration process is proceeding well.
Invivo is a pioneer in microbiome testing for healthcare professionals in the United Kingdom. Invivo has established a base
of over 1,700 active customers, and an engaged list of additional 5,800 prospective customers. In addition to its leading
position in Gastrointestinal micbiome testing services, Invivo has testing products spanning Vaginal, Oral and Urinary
testing, together with a targeted set of evidence-based intervention formulations.
With more than 20,000 microbiome tests sold since 2020, Invivo reported revenue of A$8.9 million for FY23 from testing
and intervention product sales. Invivo has been self-funded from its generated cashflow since inception, with no external
capital required, Invivo has been consistently operating cashflow positive.
The acquisition of Invivo aligns to Microba’s core testing services growth strategy. The United Kingdom is a key market in
the next phase of Microba’s international testing services growth strategy. Acquiring a market leading position, customer
and geographical base in the United Kingdom, together with Sonic Healthcare provides deep access to the entire UK
healthcare market spanning private practice and the public NHS environment.
Growth for MetaXplore™ healthcare testing with Australian healthcare professionals
Q2 delivered MetaXplore growth:
o Over 2,700 tests sold
o Over 1,000 registered healthcare professional accounts
The MetaXplore™ test range was developed together with healthcare professionals to address a large addressable market
with >30% of the population suffering from a disorder of gut‐brain interaction (DGBI) related to the bowel 1, and >20% of
the population estimated to suffer from a chronic health issue which may be influenced by their gut microbiome 2. The
MetaXplore™ test range can be accessed in Australia via a healthcare professional, and is expected to be delivered into the
United Kingdom through Invivo Clinical.
Microba’s advanced infectious disease test MetaPanel™ with Sonic Healthcare scheduled for national launch
The MetaPanel product is scheduled for national launch with Sonic Healthcare in the current quarter. Previous plans were
to open early Key Opinion Leader (KOL) access in December 2023, setting up for an initial NSW launch in Q3. The launch
plan has now been upgraded together with Sonic Healthcare to a national launch beginning with VIC, NSW and QLD.
In July 2023, the first distribution agreement with Sonic Healthcare was signed to deliver Microba’s advanced infectious
disease testing technology MetaPanel™ Australia-wide through the Sonic Healthcare Australia Pathology network. Across
the last two quarters Microba and Sonic have built technology integrations, logistics workflows, executed clinical test
validation procedures, interviewed clinicians and developed marketing materials together in preparation to make the
MetaPanel™ test clinically available to healthcare professionals. Further information will be shared on this product and the
commercial opportunity over the coming quarters aligned to the launch of this product.
MetaPanel™ is an advanced accredited metagenomic diagnostic test which has been designed to identify a comprehensive
panel of pathogenic microorganisms and genes to advance the standard of care in gastrointestinal infectious disease
pathology. It is expected that this could represent a significant commercial opportunity for the Company with an estimated
1
Estimated based on the prevalence of specific Disorders of the Gut-Brain Interaction across 26 countries (Av prevalence of 32.8%
DOI: 10.1111/nmo.14594), and the proportion regularly seeking medical support with one or more doctor visit per month (Average 15.4% DOI: 10.1053/j.gastro.2020.04.014).
2
Estimated based on current literature on the understanding of the role of the microbiome in chronic disease (Vijay, Amrita, and Ana M. Valdes. (2022):
489-501. DOI: 10.1038/s41430-021-00991-6) and burden of these chronic diseases (Australian Bureau of Statistics (2020-21), Health Conditions Prevalence,
ABS Website, accessed 20 March 2023.).
Microba Life Sciences Ltd ABN 82 617 096 652
Level 10, 324 Queen Street, Brisbane QLD 4000 Australia
T: 1300 974 621 E: investor@microba.com W: microba.com
ASX Announcement
30 January 2024
initial target market of over 16 million patients 3 globally which are high-risk and susceptible to gastrointestinal infection,
and receive routine testing for pathogens.
Growth in international revenue
International Personal Testing revenue up 321% on pcp, driven by growth of partner sales, expanding distribution partner
network and recent Invivio Clinical acquisition. Major partner SYNLAB, Europe’s largest medical diagnostic company,
revenue up 115% on pcp, driven principally by sales in Spain, Italy and Hungary.
Inflammatory Bowel Disease Program – Successful Phase I Clinical Trial.
In December 2024, the Phase I clinical trial of lead drug candidate MAP 315 was completed on schedule, demonstrating it is
safe and well tolerated at both low and high doses.
Summary of key MAP 315-001 study results:
•
•
•
•
•
•
•
•
MAP 315 had a favourable safety and tolerability profile across both low and high dose cohorts.
There were no clinically significant safety signals from safety assessments including ECGs and laboratory analysis of
haematology, coagulation, clinical chemistry or urinalysis parameters.
There was no evidence of translocation of MAP 315 into the bloodstream.
There was no impact on inflammatory biomarkers.
All participants completed the study and all dosing.
All reported adverse events (AEs) were mild (e.g. headache), with a higher proportion reported in the placebo group
and there were no AEs that lead to study discontinuation or drug withdrawal.
Treatment related AEs were minimal, transient and comparable between the MAP 315 and placebo treatment
groups.
Ongoing assessment of faecal kinetics by metagenomic analysis detects the presence of MAP 315 at the terminal
28-day analysis timepoint, 14 days after the completion of dosing, indicating the ability to successfully deliver live
MAP315 into the gastrointestinal tract.
Recent preclinical characterisation data, together with these Phase I clinical study results provide strong positive support for
continuing to advance the clinical development of MAP 315 for the treatment of Ulcerative Colitis. Data from the trial is
expected to be formulated and submitted for peer review publication. Preparation for a Phase 2 trial is well advanced, and
the team are active in market exploring options in relation to the Phase 2 strategy.
MAP 315 is being developed for the treatment of Ulcerative Colitis (UC), a debilitating form of Inflammatory Bowel Disease
(IBD) with >50% of patients unable to achieve sustained remission with current standard of care. The market for UC
treatment was valued at US$7.5b in 2020 and is forecast to grow to US$10.8b by 2030 4.
The Phase I trial is a randomised, double-blind, placebo-controlled study to evaluate the safety, tolerability and
pharmacokinetics of MAP 315 in healthy adults. The trial involves 32 healthy participants and is being conducted by Nucleus
Network, utilising their world-class clinical trial facilities in Melbourne.
IBD is a term for conditions that cause prolonged inflammation of the digestive tract and now affects more than 7 million
3
Estimated based on the global number of immuno-compromised patients and other patients at high risk for gastrointestinal infection (>8.1m global and
>68k Australian chemotherapy treated solid tumour cancer patients, and >1.1m global and >8k Australian haematological cancer patients
DOI:https://doi.org/10.1016/S1470-2045(19)30163-9 & https://www.aihw.gov.au/reports/cancer/cancer-in-australia-2021/summary), (>3m global and
12k Australian dialysis patients DOI: 10.1038/s41581-022-00542-7 & https://www.anzdata.org.au/wpcontent/uploads/2019/09/c04_haemodialysis_2018_ar2019_v2.0_2020619.pdf & https://www.anzdata.org.au/wpcontent/uploads/2021/09/c05_peritoneal_2020_ar_2021_Chapter_v1.0_20220530_Final.pdf), (>140k global and >1k Australian Organ Transplant patients
per year https://www.transplant-observatory.org/ & https://www.health.gov.au/topics/organ-and-tissue-donation/organ-and-tissue-donation-inaustralia), (>3.5m global and >25k long stay ICU patients – estimate based on data from https://ourworldindata.org/grapher/intensive-care-beds-per100000 and other sources).
4
https://www.nature.com/articles/d41573-021-00194-5 , https://www.alliedmarketresearch.com/ulcerative-colitis-market
Microba Life Sciences Ltd ABN 82 617 096 652
Level 10, 324 Queen Street, Brisbane QLD 4000 Australia
T: 1300 974 621 E: investor@microba.com W: microba.com
ASX Announcement
30 January 2024
people globally, with this number increasing each year 5. UC is one of the two major forms of IBD which results in
inflammation and ulcers (sores) in the digestive tract, causing a debilitating chronic condition. Patients are currently treated
with anti-inflammatory and immunomodulatory medication to dampen the disease and control symptoms, often with
significant side effects. These available treatment options commonly fail, with more than 50% of patients unable to achieve
sustained remission 6, which sees them experiencing regular episodes of inflammation, diarrhoea, bleeding and abdominal
pain 7. As many as 25% of patients require hospitalisation 8.
Microba’s novel drug candidate MAP 315 was originally identified using the Company’s data-driven Therapeutic Platform,
demonstrating that this previously unidentified novel bacterial species is commonly observed in healthy individuals but
consistently deficient in individuals with IBD, and in particular UC. Subsequent pre-clinical investigation of MAP 315 through
both in vitro and in vivo models demonstrated that MAP 315 promotes epithelial restitution and mucosal healing –
biological activities that are associated with disease remission but not adequately addressed through existing therapy. MAP
315 provides a compelling commercial opportunity to fill a key gap in the current standard of care for UC treatment and
represents a potential novel treatment paradigm for patients living with this debilitating disease.
Immuno-Oncology Program – Multiple immunological pre-clinical experiments completed to support candidate selection
Microba’s Immuno-Oncology Program has completed multiple pre-clinical experiments for its therapeutic leads in across
recent quarters confirming their anti-tumour activity. This involved testing in a refractory mouse model of melanoma,
demonstrating a significant reduction in tumour volume. Subsequently, in a second experiment using an ICI responsive
colon adenocarcinoma MC38 syngeneic mouse model, it was demonstrated again that Microba’s therapeutic leads are able
to significantly reduce tumour burden compared to ICI alone or controls. Further, immunological studies from the first
model in the B16-F10 mouse tumour model completed over Q2 supported prior observations and strengthened results
demonstrating activity consistent with induction of a specific and targeted immune response including:
•
Changes in cytokine and chemokine profiles consistent with anti-tumour activity; and
•
Identification of significantly enhanced immune cell infiltration by immunohistochemistry in microbiome and ICI
treated animals compared to ICI alone
Microba continues to advance these studies with a goal to enable selection of a therapeutic candidate in the first half of
2024. This includes a partnership with Assoc Prof Fernando Guimaraes from The University of Queensland to allow a
detailed examination of the immunological mechanism of action.
This program is targeting the development of a therapeutic to improve response rates in cancer patients receiving ICI
therapy. Global ICI sales continue to grow, with Merck announcing sales of the market-leading drug Keytruda of US$20.9b
for calendar year 2022 9.
While there have been considerable advances in the treatment options for melanoma, improvement of overall response
rates and survival remain meaningful areas of opportunity. Furthermore, ICIs are used in a range of cancers beyond
melanoma including lung, head and neck, breast, colon, cervical, and other types of cancer. With the ICI market being
valued at over US$30b with a >15% CAGR 10, a microbiome-based adjuvant therapy that increases response to these drugs
has the potential to become standard of care across a range of cancers, and therefore represents a substantial commercial
opportunity for Microba.
There is an increasing body of literature supporting a key role for the microbiome in cancer 11. Cancer immunotherapy, and
more specifically ICIs have become standard of care for a range of tumour types. However, despite their impact on cancer
https://www.thelancet.com/journals/langas/article/PIIS2468-1253(19)30333-4/fulltext.
https://www.crohnscolitisfoundation.org/sites/default/files/2019-02/Updated%20IBD%20Factbook.pdf.
7
Scribano, M.L. Adverse events of IBD therapies. Inflamm Bowel Dis. (2008). https://doi.org/10.1002/ibd.20702.
8
Pola, S. et al. Strategies for the care of adults hospitalized for active ulcerative colitis. Clin Gastroenterol Hepatol. (2012).
https://doi.org/10.1016/j.cgh.2012.07.006.
9
https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2022-financial-results/.
10
https://au.finance.yahoo.com/news/immune-checkpoint-inhibitors-market-predicted-090000312.html.
11
Sepich-Poore e al. (2021). The microbiome and human cancer. DOI: 10.1126/science.abc4552.
5
6
Microba Life Sciences Ltd ABN 82 617 096 652
Level 10, 324 Queen Street, Brisbane QLD 4000 Australia
T: 1300 974 621 E: investor@microba.com W: microba.com
ASX Announcement
30 January 2024
treatment, up to 70% of patients do not respond to these drugs 12,13 leaving a large, underserved patient population.
Differences in the microbiomes of responders and non-responders to ICI treatment have been observed in international
studies, and treatment of the microbiome using faecal microbiome transplants has demonstrated the ability to turn ICI nonresponders into responders 14,15. This presents an important opportunity for Microba to leverage its proprietary
Therapeutics Platform to identify the key components of the microbiome which drive that effect and develop an effective
adjuvant therapy to improve ICI response. In addition to the potential large commercial opportunity for this program, these
results provide another validation of Microba’s unique ability to discover therapeutically active biology from the human
microbiome through the Company’s platform.
Autoimmune Disease Program – Stage 1 Screening Complete.
The autoimmune disease discovery program with partner Ginkgo Bioworks (NYSE: DNA) achieved a key milestone with
completion of Stage 1 activity screening of lead strains.
Stage 1 activity screening analysed 182 strains selected through Microba’s data driven drug discovery platform. These
experiments have delivered a robust biological activity rate, including:
•
•
62% of strains displaying significant immunomodulatory activity; and
18% demonstrating significant impact on the inflammasome
The obtained data demonstrates that a significant number of the leads bacterial strains display potent anti-inflammatory
and/or anti-fibrotic activities. 35 strains 16 have now been selected to move into Stage 2 functional screening in the first
quarter of 2024 for expected discovery program completion in Q4 FY24 to support lead candidate selection.
Microba’s Autoimmune Disease program was established in partnership with Ginkgo Bioworks (NYSE: DNA) in FY22
following their strategic investment into Microba’s IPO, and embodies a 2-year discovery program principally targeting
three autoimmune disorders (lupus, psoriatic arthritis and autoimmune liver diseases). The partnership brought together
Microba’s unique ability to identify and isolate human gut bacteria associated with health together with the highthroughput microbial screening capabilities of Ginkgo Bioworks has created a powerful drug discovery workflow.
Autoimmune diseases are a family of more than 80 chronic and often life-threatening illnesses, which occur when the
body’s own immune system attacks the body’s healthy cells, tissues and organs. Autoimmune conditions now impact
around 5% of the population and their prevalence is rising 17. In recent years, several studies have highlighted the role of the
microbiome in the pathogenesis of autoimmune diseases 18. The global market for autoimmune disease treatments was
estimated to be US$198b in 2023 and forecast to grow to US$288b by 2028 19.
Second agreement executed with IFF to develop novel microbiome-based treatments for multiple forms of allergy
In December, Microba signed a research agreement with IFF as part of an ongoing multistage research program between
the parties to develop novel microbiome-based treatments for multiple forms of allergy.
The Research Agreement marks the second agreement between Microba and IFF, which is a follow up to the initial research
services agreement executed on 9 November 2021. Under the Initial Agreement, for Stage 1, Microba completed the
identification of lead species from which IFF was entitled to select under the Initial Agreement.
Leonardi et al. (2020). International Journal of Oncology. DOI: 10.3892/ijo.2020.5088.
Wolchok et al. (2017). New England Journal of Medicine. DOI: 10.1056/NEJMoa1709684.
14
Baruch et al. (2020). Science. DOI: 10.1126/science.abb5920.
15
Davar et al. (2021). Science. DOI: 10.1126/science.abf3363.
16 Initial selection was 36. 1 has been removed for commercial opportunity considerations. As part of the screening further down selection will occur.
17
Fugger, L.et al. Challenges, Progress, and Prospects of Developing Therapies to Treat Autoimmune Diseases. Cell. (2020).
https://doi.org/10.1016/j.cell.2020.03.007https://doi.org/10.1016/j.cell.2020.03.007.
18
De Luca, F. and Shoenfeld, Y. The microbiome in autoimmune diseases. Clin Exp Immunol. (2019). https://doi.org/10.1111/cei.13158.
19
https://www.prnewswire.com/news-releases/global-autoimmune-treatment-market-soars-to-288-32-billion-by-2028--driven-by-a-7-72-cagr-from-2023-301909189.html
12
13
Microba Life Sciences Ltd ABN 82 617 096 652
Level 10, 324 Queen Street, Brisbane QLD 4000 Australia
T: 1300 974 621 E: investor@microba.com W: microba.com
ASX Announcement
30 January 2024
IFF has now selected a number of Project Species to move forward into Stage 2. The Stage 2 project is to complete the
successful isolation of strains selected from Stage 1 and characterisation of those strains.
Over the term of the Research Agreement, IFF shall pay Microba approximately AUD $924,150. Under the Research
Agreement, IFF has an exclusive option to license strains for development and commercialization, which if executed may
result in royalty payments to Microba.
Financial Update
Unaudited revenue for the December 2023 quarter totalled $2.19m, representing 79% pcp growth with Personal Testing up
119% to $1.51m and Research Testing up 28% to $0.68m. Cash receipts for the December 2023 quarter totalled $1.85m, up
4.1% on the prior quarter and up 15.2% on pcp. The Q2 FY24 numbers include Invivo Clinical’s unaudited revenue and cash
receipts for the period of Microba’s ownership from 5 to 31 December 2023.
As at 31 December 2023, Microba had $27.85m in cash or equivalents. During the quarter the Company invested $4.04m
into the advancement of its data driven drug discovery programs (IBD, Immuno-oncology, and Autoimmune Disease).
In accordance with Listing Rule 4.7C, payments made during the quarter to related parties and their associates included in
item 6.1 of Appendix 4C was $115,467 and included Director fees.
Use of Funds
In section 7.4 of the Microba Life Sciences Prospectus, the Company provided a proposed use of funds statement for 24
months from listing. The table below shows the use of funds from IPO to the end of the most recent quarter ended 31
December 2023, the table does doesn’t include the estimated $6m FY23 R&D Tax Incentive refund, which will be offset
against the below line items.
Use of Funds
Q2 FY24
867
Prior Total
7,067
Total Expenditure
7,934
Prospectus
7,200
4,004
12,256
16,260
13,100
786
2,039
2,825
2,500
Administrative and working capital
1,965
5,321
7,286
4,700
Costs of the offer
Total
Further capital – Sonic Healthcare (Nov 22)
Further capital – Invivo Acquisition ANREO (Nov 23)
-
2,429
2,429
2,500
7,622
-
29,112
17,237
19,997
36,734
30,000
-
Global market penetration and sales growth
Data driven drug discovery
Platform technology advancement
During Q2 FY24, overall expenditure remained in line with the estimated use of funds as set out in the Prospectus, noting
that there has been an acceleration of the Company’s activities, in particular the progression towards launch of Microba’s
advanced infectious disease test MetaPanel™ with Sonic Healthcare and the acquisition of Invivo Clinical, a pioneer in
microbiome testing for healthcare professionals in the United Kingdom. This acceleration of activities has been enabled by
the additional investment made by Sonic in November 2022 and the ANREO capital raising completed in November 2023.
Microba Life Sciences Ltd ABN 82 617 096 652
Level 10, 324 Queen Street, Brisbane QLD 4000 Australia
T: 1300 974 621 E: investor@microba.com W: microba.com
ASX Announcement
30 January 2024
This announcement has been authorised for release by the Board.
For further information, please contact:
Dr Luke Reid
Chief Executive Officer
E: Luke.Reid@microba.com
Investor / Media Relations
E: investor@microba.com
W: https://ir.microba.com/
Join our Investor Mailing List
About Microba Life Sciences Limited
Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology
for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for
major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers.
Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the
microbiome, health and disease for the development of new health solutions.
For more information visit: www.microba.com
Microba encourages all current investors to go paperless by registering their details with the designated registry service
provider, Automic Group, whose contact information is housed on the Investor Relations page of the Company’s website.
Microba Life Sciences Ltd ABN 82 617 096 652
Level 10, 324 Queen Street, Brisbane QLD 4000 Australia
T: 1300 974 621 E: investor@microba.com W: microba.com
Rule 4.7B
Appendix 4C
Quarterly cash flow report for entities
subject to Listing Rule 4.7B
Name of entity
Microba Life Sciences Limited, and controlled entities
ABN
Quarter ended (“current quarter”)
82 617 096 652
31 December 2023
Consolidated statement of cash flows
Current quarter
$A’000
1.
Cash flows from operating activities
1.1
Receipts from customers
1.2
Payments for
Year to date
(6 months)
$A’000
1,854
3,635
(3,742)
(6,703)
(b) product manufacturing and operating
costs
(904)
(1,637)
(c) advertising and marketing
(386)
(774)
(d) leased assets
(176)
(331)
(e) staff costs
(1,876)
(4,416)
(f)
(1,594)
(2,085)
(a) research and development
administration and corporate costs
1.3
Dividends received (see note 3)
1.4
Interest received
214
437
1.5
Interest and other costs of finance paid
(6)
(12)
1.6
Income taxes paid
-
-
1.7
Government grants and tax incentives
18
26
1.8
Other (provide details if material)
-
-
1.9
Net cash from / (used in) operating
activities
(6,598)
(11,860)
2.
Cash flows from investing activities
2.1
Payments to acquire or for:
(9,574)
(9,574)
-
-
(50)
(153)
-
-
(831)
(1,554)
-
-
(a) entities
(b) businesses
(c) property, plant and equipment
(d) investments
(e) intellectual property
(f)
other non-current assets
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 1
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Consolidated statement of cash flows
2.2
Current quarter
$A’000
Year to date
(6 months)
$A’000
Proceeds from disposal of:
(a) entities
-
-
(b) businesses
-
-
(c) property, plant and equipment
-
-
(d) investments
-
-
(e) intellectual property
-
-
(f)
-
-
other non-current assets
2.3
Cash flows from loans to other entities
-
-
2.4
Dividends received (see note 3)
-
-
2.5
Other (provide details if material)
-
-
2.6
Net cash from / (used in) investing
activities
(10,455)
(11,281)
3.
Cash flows from financing activities
3.1
Proceeds from issues of equity securities
(excluding convertible debt securities)
20,357
20,357
3.2
Proceeds from issue of convertible debt
securities
-
-
3.3
Proceeds from exercise of options
-
-
3.4
Transaction costs related to issues of
equity securities or convertible debt
securities
(1,246)
(1,246)
3.5
Proceeds from borrowings
-
-
3.6
Repayment of borrowings
(144)
(238)
3.7
Transaction costs related to loans and
borrowings
-
-
3.8
Dividends paid
-
-
3.9
Other (provide details if material)
-
-
3.10
Net cash from / (used in) financing
activities
18,967
18,873
4.
Net increase / (decrease) in cash and
cash equivalents for the period
4.1
Cash and cash equivalents at beginning of
period
25,952
25,952
4.2
Net cash from / (used in) operating
activities (item 1.9 above)
(6,597)
(11,860)
4.3
Net cash from / (used in) investing activities
(item 2.6 above)
(10,455)
(11,281)
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 2
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Consolidated statement of cash flows
Current quarter
$A’000
Year to date
(6 months)
$A’000
4.4
Net cash from / (used in) financing activities
(item 3.10 above)
18,967
18,873
4.5
Effect of movement in exchange rates on
cash held
(21)
70
4.6
Cash and cash equivalents at end of
period
27,846
21,754
5.
Reconciliation of cash and cash
equivalents
Current quarter
$A’000
Previous quarter
$A’000
at the end of the quarter (as shown in the
consolidated statement of cash flows) to the
related items in the
Share your feedback
Discover